Category: 1620510-51-1

On March 30, 2021, Guo, Hongli; Chen, Tao; Zhou, Feng; Gao, Daxin; Chen, Dawei published a patent.Reference of (R)-(4-Methylmorpholin-3-yl)methanol The title of the patent was Preparation of quinazoline-based compounds as KRAS G12C inhibitor for treatment and/or alleviation of KRAS G12C-related diseases. And the patent contained the following:

The present invention relates to preparation of quinazoline-based compounds as KRAS G12C inhibitor for treatment and/or alleviation of KRAS G12C-related diseases. In particular, the quinazoline-based compound I (wherein, α and β bonds are single bonds or double bonds, resp.; X = N or CR2; when the β bond is a single bond, Y = C(O) and Z = NR3; when the β bond is a double bond, Y and Z are independently N or CR2; when the α bond is a single bond, W = N and V = CH2 or C(O); when the a bond is a double bond, W = C and V = CR4 or N; U and M are each independently N, C or CH; ring A = Ph, 3-8 membered cycloalkyl, 5-6 membered heteroaryl or 4-8 membered heterocycloalkyl group; the A ring is unsubstituted or optionally substituted). Further, (ring B = 5-10 membered heterocycloalkyl; the B ring is unsubstituted or optionally substituted; R = C6-10 aryl, 5-10 membered heteroaryl or 9-14 membered fused heterocycloalkyl group; said R is unsubstituted or optionally substituted; R1 = C2-4 alkenyl, C2-4 alkynyl or partially unsaturated C4-6 cycloalkyl; said R1 is unsubstituted or optionally substituted; R2 = H, hydroxyl, halogen, cyano, amino etc.; R3 = C3-8 cycloalkyl, 3-8 membered heterocycloalkyl, C6-10 aryl, 5-10 heteroaryl, C3-8 cycloalkyl-C1-4 alkyl etc.; R4 = H, hydroxyl, halogen, C2-6 alkenyl, C2-6 alkynyl, cyano, amino etc.), its isomers, stable isotope derivatives or pharmaceutically acceptable salts were prepared The inventive compound and its composition disclosed can effectively treat diseases related to KRAS G12C, such as cancer. The experimental process involved the reaction of (R)-(4-Methylmorpholin-3-yl)methanol(cas: 1620510-51-1).Reference of (R)-(4-Methylmorpholin-3-yl)methanol

The Article related to quinazoline compound preparation kras g12c inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Reference of (R)-(4-Methylmorpholin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On November 29, 2018, Li, Liansheng; Feng, Jun; Wu, Tao; Liu, Yuan; Wang, Yi; Ren, Pingda; Liu, Yi published a patent.SDS of cas: 1620510-51-1 The title of the patent was Preparation of substituted quinazolines as covalent inhibitors of KRAS. And the patent contained the following:

The title compounds I [G1 and G2 = (independently) N or CH; L1 = a bond or NR6; L2 = a bond or alkylene; L3 = a bond, O, NR6, S, S(O) or SO2; R1 = unsubstituted naphthyl or optionally substituted quinolinyl when at least one of R31, R32, R41 and R42 is not H; or R1 = II (A1-A4 = (independently) C or N; X = O, S, N, etc.;Y = O, S, N, etc.; Z = O, S, N, etc.; one of R11-R14 is a covalent bond to the carbon attached to R1, and the other of R11-R14 = (independently) H, NH2, CN, etc.; R21-R23 = (independently) H, NH2, CN, etc.; R31 and R32 = (independently) H, OH, NH2, etc.; R41 and R42 = (independently) H, OH, NH2, etc.; R5 = NH2, CN, OH, etc.; R6 = (independently) H or alkyl; m and n = (independently) 1-3; and E = an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein)] or pharmaceutically acceptable salts, isotopic forms, stereoisomers or prodrugs thereof, having activity as inhibitors of G12C mutant KRAS protein, were prepared E.g., a multi-step synthesis of (2R,5S)-III, starting from 2-amino-4-bromo-3-fluorobenzoic acid, was described. Representative compounds I were tested and found to covalently bind to (or modify) KRAS G12C after a ten minute incubation period (data given). Pharmaceutical compositions comprising compounds I, and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, were also provided. The experimental process involved the reaction of (R)-(4-Methylmorpholin-3-yl)methanol(cas: 1620510-51-1).SDS of cas: 1620510-51-1

The Article related to quinazoline preparation g12c mutant kras inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 1620510-51-1

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 31, 2013, Xia, Guangxin; Shen, Jingkang; Yu, Yongping; Chen, Wenteng; Zhang, Chunchun; Hao, Yu; Zhang, Jing; Li, Bojun; Liu, Xuejun published a patent.Synthetic Route of 1620510-51-1 The title of the patent was Quinazoline derivatives as protein tyrosine kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. And the patent contained the following:

Disclosed are quinazoline derivatives of formula I and their pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, and prodrugs. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivatives, and an application thereof. The quinazoline derivatives of the invention are provided with improved anti-tumor activity. Compounds of formula I wherein R1 is (un)substituted C6-10 aryl, (un)substituted C3-12heteroaryl; R2 is H, halo, OH, amino, C1-6 (halo)alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, etc.; X is halo; R3 and R4 are independently H, C1-6 alkyl, R6R7N-(CH2)1-3-, R6R7N-(CH2)1-2-Y-(CH2)0-4- and Het-W-(CH2)0-2-; R6 and R7 are independently H, C1-6 alkyl, Het-W-(CH2)0-2- and R8-W-(CH2)0-4-; R8 is H, and C1-6 alkyl; Y is O, S and NH and derivatives; Z is NH and derivatives and O; W is NH and derivatives, O and a single bond; Het is 3- to 6-membered heterocyclic ring and 5-membered nitrogen-containing heteroaryl; and their pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, and prodrugs thereof, are claimed. Compounds of formula I were prepared by using condensation and Wittig olefination as the key steps. All the invention compounds were evaluated for their protein tyrosine kinase inhibitory activity. From the assay, it was determined that example compound II exhibited the IC50 value of 1.3, 75 and 23 nM against EGFR, HER2 and HER4, resp. The experimental process involved the reaction of (R)-(4-Methylmorpholin-3-yl)methanol(cas: 1620510-51-1).Synthetic Route of 1620510-51-1

The Article related to quinazoline preparation protein tyrosine kinase inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Synthetic Route of 1620510-51-1

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On October 29, 2020, Siegel, Stephan; Siegel, Franziska; Schulze, Volker; Berger, Markus; Graham, Keith; Suelzle, Detlev; Boemer, Ulf; Korr, Daniel; Schroeder, Jens; Moenning, Ursula; Niehues, Michael; Meyerson, Matthew; Greulich, Heidi; Kaplan, Bethany published a patent.Synthetic Route of 1620510-51-1 The title of the patent was Preparation of 4H-pyrrolo[3,2-c]pyridin-4-one derivatives as EGFR inhibitors. And the patent contained the following:

Title compounds I [wherein X and Y independently = O or (un)substituted NH; R1 = Me, Et, or CF3, etc.; R2 = H, Me, or Et, etc.; R3 = H or F; R4 = H or Me; R5 = H, CF3, or C1-3 alkyl, etc.; A = (HCR6)n, n is 0 or 1; R6 = H, C1-3 alkyl, or C1-3 haloalkyl], and their pharmaceutically acceptable salts thereof, were prepared as EGFR inhibitors. Thus, the invention compound I (X = Y = O; R1 = OMe; R2 = Cl; R3 = H; R4 = H; R5 = H; A = absence) was prepared and gave a mutEGFR inhibition IC50 value of 1.59E-10 mol/L in D770_N771insSVD kinase assay. The experimental process involved the reaction of (R)-(4-Methylmorpholin-3-yl)methanol(cas: 1620510-51-1).Synthetic Route of 1620510-51-1

The Article related to pyrrolopyridinone antitumor preparation egfr inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Synthetic Route of 1620510-51-1

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts